A woman in her 40s with a history of a subarachnoid haemorrhage complicated by ischaemic infarcts presented with 1 week of ...

Dr. Kimberly Trotter distilled four high-impact disease clusters—gout, rheumatoid arthritis (RA), systemic lupus ...

The pending Supreme Court challenge to the Affordable Care Act's preventive services mandate has serious implications for the ...

Hawai‘i Island Community Health Center has made a stunning medical breakthrough, achieving a 71% cure rate for Hepatitis C — ...

Stigma around disease may prevent people from getting the help they need but there are ways to fight it. Watch this video to ...

Mobile units are being used to test for hepatitis C in one of the areas where the virus is thought to be particularly ...

In 2019, the FDA approved Mavyret to shorten the once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients across all ...

FDA Expands Mavyret Use to Acute Hepatitis C: Mavyret is now the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C (HCV) in patients aged three years and ...

Here's a new summary of all the drugs in the pipeline currently being evaluated for the treatments of vasculitis.

Viral hepatitis is largely preventable and can be treated, though there are inequities in access to vaccines, diagnostics, and treatments, and most people living with hepatitis are unaware that ...

Mavyret is a fixed dose combination of the direct-acting antiviral agents, glecaprevir, a HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.